Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Twist Bioscience ( (TWST) ) has issued an update.
On August 5, 2025, Twist Bioscience appointed Trynka Shineman Blake to its Board of Directors, where she will also serve on the Audit Committee. Ms. Shineman Blake, with her extensive experience in corporate governance and digital transformation, is expected to contribute significantly to Twist’s strategic direction as the company aims for adjusted EBITDA breakeven and continued innovation. Her previous leadership roles at Vistaprint highlight her ability to drive growth and innovation, aligning with Twist’s customer-centric growth strategy.
The most recent analyst rating on (TWST) stock is a Buy with a $56.00 price target. To see the full list of analyst forecasts on Twist Bioscience stock, see the TWST Stock Forecast page.
Spark’s Take on TWST Stock
According to Spark, TipRanks’ AI Analyst, TWST is a Neutral.
Twist Bioscience is showing strong revenue growth and strategic advancements, particularly with the DNA data storage spinout. Despite these positives, the company struggles with profitability, evident from its negative P/E ratio and weak technical indicators. Improving operational efficiencies and cash flow management will be key to enhancing the stock’s attractiveness.
To see Spark’s full report on TWST stock, click here.
More about Twist Bioscience
Twist Bioscience Corporation operates in the synthetic biology industry, providing innovative silicon-based DNA synthesis platforms. These platforms enable precision, cost-effective, and high-throughput synthesis, sequencing, and therapeutics discovery, serving fields such as medicine, agriculture, and industrial chemicals.
Average Trading Volume: 1,156,605
Technical Sentiment Signal: Sell
Current Market Cap: $1.66B
See more data about TWST stock on TipRanks’ Stock Analysis page.